Fred Hutch’s Infectious Disease Sciences Program is committed to promoting timely discussions and efficient communication of the latest advances in research and clinical care, among colleagues and collaborators worldwide.
To support this goal, we host several recurring symposia that attract internationally-recognized leaders in the field, as well as unique, one-time events. Our Symposium on Infectious Diseases in the Immunocompromised Host is a rare opportunity for clinicians, researchers and trainees to discuss infectious diseases specifically within immunosuppressed patients, driving knowledge advancement and dissemination. Likewise, the 2018 inaugural Microbiome Research Initiative Symposium brought together investigators doing exemplary research on the impact of the microbiome on cancer, including transplant outcomes, nutrition and metabolites, carcinogenesis, and immune therapy. In 2018, we also hosted the Farm to Bedside Symposium, inviting the community to join us in learning about antibiotic resistance from investigative journalist Maryn McKenna and a panel of leading researchers and health professionals.
Upcoming Event
Your search for "" did not match any of our events. Please try another event term or combination of terms and filters.
Photo Highlights of the 4th Symposium on Infectious Diseases in the Immunocompromised Host
David Fredricks, MD moderating panel.
Poster session.
Best abstract award winners.
Discussion with Steve Pergam, MD, MPH.
Trainee attendees.
Networking reception at the Seattle Art Museum.
General session.
Registration check in materials.
Scientific Organizing Committee members.
David Fredricks, MD moderating panel.
Poster session.
Best abstract award winners.
Discussion with Steve Pergam, MD, MPH.
Trainee attendees.
Networking reception at the Seattle Art Museum.
General session.
Registration check in materials.
Scientific Organizing Committee members.
Past Events
On September 10th, experts from academia, government, advocacy, and industry settings gathered to hear from eight speakers and participated in four panel discussions in shared recognition of the importance of working to prevent and treat infections in immunocompromised patients. The inagural event included participants from 35 institutions. The workshop discussed a vision for a network focused on immunotherapuetic approaches to prevent and treat infections in immunocompromised patients.
Welcome
Joshua A. Hill, MD, FIDSA | Fred Hutch Cancer Center
Gaps & Opportunities for Trials in Immunocompromised Individuals at the Intersection of Science and Public Health
The Clinical Need and Opportunities for a Dedicated Network to Conduct Efficacy and Treatment Trials for Pandemic and Endemic Infectious Diseases in Immunocompromised Patients
Michael Boeckh, MD, PhD | Fred Hutch Cancer Center
COVID-19: A Case Study of Missed Opportunity and Peril among the Immunocompromised
Larry Corey, MD | Fred Hutch Cancer Center
Opportunities and Possibilities for a Collaborative Network to Facilitate Vaccine Studies and Data Generation in Immunocompromised Patient Populations
David C. Kaslow, MD | FDA
Panel Discussion: Gaps & Opportunities
Stakeholder Perspectives on Strategies to Advance Evidence Generation in Immunocompromised Individuals
The Ongoing Pandemic for Cancer Patients and Impact on Quality of Life
Kaley Childs Karaffa | Patient and Family Engagement
How to Provide Public Health Guidance with Minimal Data, and Implications for Access (Label Indication) and Coverage (Insurance) from the Lens of the Advisory Committee on Immunization Practices (ACIP)
Camille Kotton, MD | Massachusetts General Hospital
Industry Perspectives on Drug Development in Immunocompromised Individuals
Lisa Glasser, MD | AstraZeneca
Panel Discussion: Stakeholder Perspectives
Identifying Our Goals, Initial Focus, Structure and Partners
Crowdsourcing a Vision for a Network to Study Immunotherapeutics for Infectious Diseases in Immunocompromised Individuals: Patient Populations, Pathogens, Structure/Governance, and High Priority Trials
Joshua A. Hill, MD, FIDSA | Fred Hutch Cancer Center
Panel Discussion: Goals, Focus & Structure
Moving from Vision to Reality: Generating Support and Obtaining Funding
A Framework for SeroNet and HPV Serology Standardization as a Network Model of Public-Private Partnerships
Ligia Pinto, PhD | Frederick National Laboratory for Cancer Research
Historical Insights from the HVTN: How to Build and Launch the Ship
Larry Corey, MD | Fred Hutch Cancer Center
Panel Discussion: Generating Support
Closing
Michael Boeckh, MD, PhD | Fred Hutch Cancer Center
May 1-2nd, an audience of 275 doctors, researchers, pharmacists, advanced-practice providers and medical trainees gathered to hear from 48 speakers in shared recognition of the importance of working to mitigate serious complications in immunocompromised individuals. The international event included participants from over one hundred institutions, thirteen countries, and six continents. The symposium addressed COVID-19, Cytomegalovirus and Human Herpesvirus-6, Fungal Disease, Immunotherapy, Respiratory Virus Disease, Antimicrobial Resistance and Microbiome, and Vaccines. Speakers also discussed case presentation and round table discussions with audience participation within these subject areas. Seventy-one trainees were able to attend the symposium as a part of the travel stiped program.
Introduction
Co-chairs: Michael Boeckh, Catherine Liu, Joshua Schiffer
Fred Hutch Cancer Center, University of Washington
Keynote Address
Introduction: Michael Boeckh, Fred Hutch Cancer Center, University of Washington
COVID-19 Vaccines in Immunocompromised Patients
Lindsey Baden, Brigham and Women's Hospital, Dana Farber Cancer Institute, Harvard University
COVID-19
Chairs: Catherine Liu, Fred Hutch Cancer Center, University of Washington
Helen Chu, University of Washington
COVID-19 in Immunocompromised Hosts: Outcomes and Therapeutic Management Strategies
Ghady Haidar, University of Pittsburgh
Case Presentation and Round Table Discussion (with audience response system): Challenges in Management of COVID-19 in Immunocompromised Hosts— Protracted Infection and Persistent Viral Shedding
Discussants:
Catherine Liu, Fred Hutch Cancer Center, University of Washington
Helen Chu, University of Washington
Ghady Haidar, University of Pittsburgh
Madeleine Heldman, Duke University
Mini Kamboj, Memorial Sloan Kettering
Cytomegalovirus and Human Herpesvirus-6 — New Approaches
Chairs: Ajit Limaye, University of Washington
Danniel Zamora, Fred Hutch Cancer Center, University of Washington
CMV After Hematopoietic Cell Transplantation: New Drugs and Immune Monitoring
Roy Chemaly, MD Anderson Cancer Center
CMV in Solid Organ Transplant Recipients: New Drugs and Immune Monitoring
Joanna Schaenman, University of California Los Angeles
HHV-6 Pulmonary Disease: What is the Evidence?
Joshua Hill, Fred Hutch Cancer Center, University of Washington
Case Presentation and Round Table Discussion (with audience response system): A Challenging Case of Resistant CMV Infection
Case Presenter: Danniel Zamora, Fred Hutch Cancer Center, University of Washington
Discussants:
Joshua Hill, Fred Hutch Cancer Center, University of Washington
Genovefa Papanicolaou, Memorial Sloan Kettering Cancer Center
Michael Boeckh, Fred Hutch Cancer Center, University of Washington
Roy Chemaly, MD Anderson Cancer Center
Danniel Zamora, Fred Hutch Cancer Center, University of Washington
Ajit Limaye, University of Washington
Fungal Disease
Chairs: Monica Slavin, MacCallum Cancer Centre, Melbourne, Australia
Ricardo La Hoz, UT Southwestern Medical Center
New Antifungal Agents
Dimitrios Kontoyiannis, MD Anderson Cancer Center
Case Presentation and Round Table Discussion (with audience response system): Controversies in Fungal Management (Mucor Therapy, Threshold for Proceeding to Transplantation)
Discussants:
David Fredricks, Fred Hutch Cancer Center, University of Washington
Monica Slavin, MacCallum Cancer Centre, Melbourne, Australia
Dimitrios Kontoyiannis, MD Anderson Cancer Center
Julian Lindsay, Fred Hutch Cancer Center
Ricardo La Hoz, UT Southwestern Medical Center
Immunotherapy
Chairs: Joshua Hill, Fred Hutch Cancer Center, University of Washington
Madeleine Heldman, Duke University
Best Trainee Abstract
Infections in CAR T-Cell Recipients
Muhammad Bilal Abid, Medical College of Wisconsin
Advances in Virus-Specific Immunotherapy
Genovefa Papanicolaou, Memorial Sloan Kettering Cancer Center
Keynote Address
Introduction: Per Ljungman, Karolinska Institutet, Stockholm, Sweden
Respiratory Virus Vaccinations in Immunocompromised Hosts
Janet Englund, Seattle Children's Hospital, University of Washington
Respiratory Virus Disease
Chairs: Angela Campbell, Centers for Disease Control and Prevention
Per Ljungman, Karolinska Institutet, Stockholm, Sweden
Impact of Respiratory Viruses in Hematopoietic Cell Transplantation and Hematology/Oncology Patients During COVID-19 and Beyond
Alpana Waghmare, Seattle Children's Hospital, University of Washington, Fred Hutch Cancer Center
Impact of Respiratory Viruses in Solid Organ Transplant Patients During COVID-19 and Beyond
Lara Danziger-Isakov, Cincinnati Children’s Hospital Medical Center
Case Presentation and Round Table Discussion (with audience response system): To Delay or Not Delay Transplantation
Discussants:
Alpana Waghmare, Seattle Children's Hospital, University of Washington, Fred Hutch Cancer Center
Per Ljungman, Karolinska Institutet, Stockholm, Sweden
Angela Campbell, Centers for Disease Control and Prevention
Cynthia Fisher, University of Washington
Lara Danziger-Isakov, Cincinnati Children’s Hospital Medical Center
Michael Ison, National Institute of Allergy and Infectious Diseases
Antiviral Treatment (Including COVID-19)
Michael Ison, National Institute of Allergy and Infectious Diseases
Monoclonal Antibodies (Including COVID-19)
Jim Boonyaratanakornkit, Fred Hutch Cancer Center, University of Washington
Keynote Address
Introduction: David Fredricks, Fred Hutch Cancer Center, University of Washington
Advances in Fecal Microbiota Transplantation for the Eradication of Multidrug-Resistant Organisms and Treatment of Graft-Versus-Host Disease
Julian Marchesi, Imperial College London, England
Antimicrobial Resistance and Microbiome
Chairs: David Fredricks, Fred Hutch Cancer Center, University of Washington
Stephanie Pouch, Emory University
Challenges and Opportunities for Management of Antimicrobial Resistance in the Immunocompromised Host
Judith Anesi, University of Pennsylvania
Phage Therapy for Multidrug-Resistant Organisms
Saima Aslam, University of California San Diego
Vaccines
Chairs: Sanjeet Dadwal, City of Hope
Upton D. Allen, University of Toronto, The Hospital for Sick Children
Progress in Herpesvirus Vaccines: Varicella-Zoster Virus and Cytomegalovirus
Mark Schleiss, University of Minnesota
How to Approach Hesitant Patients on Vaccination
Annika Hofstetter, Seattle Children’s Hospital, University of Washington
Vaccination: Special Considerations in Immunocompromised Hosts
Steve Pergam, Fred Hutch Cancer Center, University of Washington
Closing | Co-chairs: Michael Boeckh, Catherine Liu, Joshua Schiffer
Fred Hutch Cancer Center, University of Washington
On June 10-11, 2019 a diverse audience of more than 200 doctors, researchers, pharmacists, advanced-practice providers and medical trainees gathered together in shared recognition of the importance of working to mitigate serious complications in immunocompromised individuals. The event featured outstanding, internationally recognized experts in the field, representing more than 23 institutions, who spoke on topics including infections in solid organ transplant, hematopoietic cell transplant and oncology. The symposium addressed fungal disease, respiratory viruses, C. difficile, CMV, immunotherapy, the microbiome, and antimicrobial stewardship. Speakers covered controversies in the field through multiple panel discussions and a pro/con debate with audience response opportunities for an interactive two-day symposium.
Event Schedule
Day 1 Introduction
Michael Boeckh | Fred Hutch, University of Washington
Keynote Address
Native Indigenous Protective Factors of the Microbiome Against Clostridium difficile
Casey Theriot | North Carolina State University
Clostridium Difficile and the Microbiome
Chairs
David Fredricks | Fred Hutch, University of Washington
Steven Pergam | Fred Hutch, University of Washington
Pre-transplant Intestinal Microbial Diversity Predicts Critical Illness After Hematopoietic Cell Transplantation
Fatima Adhi | Cleveland Clinic
Clostridium difficile and Fecal Microbiota Transplantation
Krishna Rao | University of Michigan
Pro/Con Debate: What is the Optimal Approach for Detection of Clostridium difficile Infection — Especially in Immunocompromised Patients?
Moderators:
David Fredricks | Fred Hutch, University of Washington
Steven Pergam | Fred Hutch, University of Washington
Debators:
Ferric Fang | University of Washington, Harborview Medical Center
Christopher Polage | Duke University
Cytomegalovirus (CMV)
Chairs:
Michael Boeckh | Fred Hutch, University of Washington
Ajit Limaye | University of Washington, Fred Hutch
Managing Cytomegalovirus After Hematopoietic Cell Transplantation
Genovefa Papanicolaou | Memorial Sloan Kettering Cancer Center
Managing Cytomegalovirus in Solid Organ Transplant Recipients
Nina Singh | University of Pittsburgh
Panel Discussion: Controversies in Cytomegalovirus Management
Case presenters:
Camille Kotton | Massachusetts General Hospital
Sara Vora | Seattle Children’s Hospital
Moderators:
Michael Boeckh | Fred Hutch, University of Washington
Ajit Limaye | University of Washington, Fred Hutch
Panelists:
- Roy Chemaly | The University of Texas MD Anderson Cancer Center
- YaeJean Kim | Samsung Medical Center, Seoul, South Korea
- Francisco Marty | Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School
- Genovefa Papanicolaou | Memorial Sloan Kettering Cancer Center
Fungal Disease
Chairs:
Kieren Marr |Johns Hopkins University School of Medicine
Monica Slavin | University of Melbourne, National Centre for Infections in Cancer, Australia
A Single Center, 0pen-label Trial of Isavuconazole Prophylaxis Against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Anat Stern, Memorial Sloan Kettering Cancer Center
New Antifungal Drugs
Kieren Marr | Johns Hopkins University School of Medicine
Fungal Diagnostics
John Perfect | Duke University
Panel Discussion: Controversies in Fungal Management
Case presenters: Steven Pergam | Fred Hutch, University of Washington
Brian Fisher | Children's Hospital of Philadelphia
Moderators:
Kieren Marr | Johns Hopkins University School of Medicine
Monica Slavin | University of Melbourne, National Centre for Infections in Cancer, Australia
Panelists:
- Sanjeet Dadwal, City of Hope
- Tobias Hohl, Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Research Center*
- Dimitrios Kontoyiannis, The University of Texas MD Anderson Cancer Center
- John Perfect, Duke University
Immunotherapy
Chairs:
Issam Raad | The University of Texas MD Anderson Cancer Center
Rebecca Gardner | Seattle Children’s Hospital
Infections in CAR T Cell Recipients
Joshua Hill | Fred Hutch, University of Washington
Infections Following Novel Immunotherapies
Mark Awad | Harvard Medical School, Dana-Farber Cancer Institute
Day 2
Keynote Address
Host Transcriptomics for Infectious Disease Diagnostics
Christopher Woods | Duke University
Respiratory Virus Disease
Chairs:
Per Ljungman | Karolinska University Hospital, Karolinska Institutet, Sweden
Angela J.P. Campbell |, Centers for Disease Control and Prevention
Respiratory Viral Infection Does Not Decrease Odds of Other Microbiologically Documented Infection in Febrile Neutropenia in Children with Cancer
William Otto | The Children's Hospital of Philadelphia
Hematopoietic Cell Transplantation Recipients
Alpana Waghmare | Seattle Children's Hospital, University of Washington, Fred Hutch
Solid Organ Transplantation Recipients
Cynthia Fisher | University of Washington, Fred Hutch
Antiviral Treatment in Solid Organ Transplantation Recipients
Michael Ison | Northwestern University
Antimicrobial Stewardship
Chairs:
Catherine Liu | Fred Hutch, University of Washington
Scott Weissman | Seattle Children’s Hospital
Keynote Address
Pros and Cons of Withdrawing Quinolone Prophylaxis for the Prevention of Neutropenic Fever
Monica Slavin | University of Melbourne, National Centre for Infections in Cancer, Australia
Challenges and Opportunities for Antimicrobial Stewardship and Infection Prevention in Pediatric Hematology-Oncology/Bone Marrow Transplantation
Joshua Wolf | St. Jude’s Children’s Hospital
Multi-Drug Resistant Gram-Negative Bacteria and Asymptomatic Bacteriuria in Solid Organ Transplant Recipients
Lilian Abbo | University of Miami
Management of Neutropenic Fever: Past, Present, and Future
Susan Seo | Memorial Sloan Kettering Cancer Center
Closing Remarks
Michael Boeckh, Fred Hutchinson Cancer Research Center, University of Washington
In September 2018, Fred Hutch hosted a two-day symposium highlighting research on interactions between the microbiome and cancer. Research is revealing that the microbiome can affect susceptibility to disease, including cancer. In addition, the microbiome is linked to the success of cancer therapies and the development of infectious complications. The symposium drew 115 attendees from the Hutch, the University of Washington and other Seattle research institutions, and featured 19 speakers, including keynoter Dr. Yasmine Belkaid, director of the Microbiome Program at the National Institute of Allergy and Infectious Diseases, in Bethesda, Maryland.
Day 1 Introduction
David Fredricks | Fred Hutch, University of Washington
Greeting
Geoffrey R. Hill | Fred Hutch
Therapeutics
Moderator
Mac Cheever | Fred Hutch; University of Washington
Commensal Microbiota and Anti-Tumor Immunity
Thomas F. Gajewski | University of Chicago
Development of Microbiome Drugs for Immune Related Disorders
David Cook | Seres Therapeutics
Diet
Moderator
William R. DePaolo | University of Washington
Diet, the Microbiome, and Colon Cancer Risk
Stephen J.D. O’Keefe | University of Pittsburgh; University of Stellenbosch, South Africa
Gut Microbial Metabolism of Dietary Phytochemicals and Impact on Cancer Risk
Johanna Lampe | Fred Hutch; University of Washington
Microbiome-Encoded Targets for the Prevention of Colorectal Cancer
Neelendu Dey | Fred Hutch; University of Washington
Hematopoietic Cell Transplant
Moderator
Steven Pergam | Fred Hutch; University of Washington
Microbiome Modulation of Intestinal Barrier Function
Robert Jenq | University of Texas MD Anderson Cancer Center
Dynamics of the Gut Microbiota after Hematopoietic Cell Transplantation
David Fredricks | Fred Hutch; University of Washington
MAIT Cell Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation
Cameron Turtle | Fred Hutch; University of Washington
Panel Discussion: The Next Generation of Research
Moderator
- David Fredricks | Fred Hutch; University of Washington
Panelists
- David Cook | Seres Therapeutics
- Neelendu Dey | Fred Hutch; University of Washington
- Robert Jenq | University of Texas MD Anderson Cancer Center
- Johanna Lampe | Fred Hutch; University of Washington
- Stephen O’Keefe | University of Pittsburgh; University of Stellenbosch, South Africa
Poster Session and Reception
Day 2 Introduction
Sujatha Srinivasan | Fred Hutch
Keynote Address
Control of Tissue Immunity and Repair by the Microbiota
Yasmine Belkaid | National Institutes of Health
Basic Sciences
Moderator
Nina Salama | Fred Hutch
Acquired Interbacterial Defense (AID) Systems Encoded by Members of the Highly-Abundant Order Bacteroidales
Benjamin Ross | University of Washington
Maternal Antibodies Regulate Neonatal Intestinal Homeostasis
Meghan Koch | Fred Hutch
Tumor Microbiota in the Progression and Treatment of Colorectal Cancer
Susan Bullman | Broad Institute of Harvard and MIT
Tools & Technologies
Moderator
Neelendu Dey | Fred Hutch
Minimizing Variability and Enhancing Accuracy in Microbiome Studies
Sujatha Srinivasan | Fred Hutch
Discovering Ultrasmall Bacteria and Homeostatic Mechanisms Through Cultivation of a High Diversity Oral Community In Vitro
Jeffrey Scott McLean | University of Washington
Analytics
Moderator
Sujatha Srinivasan | Fred Hutch
A Compositional Transform Reveals HIV Exposure Induced Shifts in the Fecal Microbiota and Vaccine Responsiveness of Nigerian Infants
Bryan Brown | Seattle Children’s Research Institute
Bacterial Genome Islands in the Gut Microbiome are Reproducibly Associated with Human Health and Disease
Sam Minot | Fred Hutch
Modeling and Testing the Human Microbiome in Longitudinal Perturbation Experiments
Susan Holmes | Stanford University
Microbiomes in the Context of Personal, Dense, Dynamic Data Clouds for Human Health
Nathan Price | Institute for Systems Biology; University of Washington; Arivale
Joint Analysis of Microbiome and Other Omic Data Types
Michael Wu | Fred Hutch; University of Washington
Farm to Bedside
Presented in January 2018, Farm to Bedside featured independent journalist Maryn McKenna, author of Big Chicken: The Incredible Story of How Antibiotics Created Modern Agriculture and Changed the Way the World Eats. McKenna’s talk focused on antimicrobial resistance and the link between antibiotic use in agriculture and infections in people with compromised immune systems. Following her talk, a panel of leading infectious disease experts led a discussion about the implications of antibiotic resistance for the future of patient care, and steps we can take to prevent the further development and spread of resistance.
Our 2nd Symposium on Infectious Diseases in the Immunocompromised Host grew to a 2-day event with an expanded audience, increased trainee participation, and a broader range of critically relevant topics. More than 30 esteemed speakers provided their expertise as leaders in the field and gave our audience a chance to celebrate significant accomplishments in the field of infectious disease in the immunocompromised host. Forty-eight trainees were able to attend the symposium as part of our expanded travel stipend program.
Day 1 Introduction
Michael Boeckh | Fred Hutch; University of Washington
Keynote Address
Vaccine and Monoclonal Antibodies for CMV Prevention in Transplant Recipients
Paul Griffiths | University College London Medical School
Vaccines and Immunotherapy
Chair
Lawrence Corey | Fred Hutch; University of Washington
Immunologic Control of CMV in Transplantation
John Zaia | City of Hope National Medical Center
Adoptive T Cell Therapy for Viral Infections
Ann Leen | Baylor College of Medicine
Infections Following CAR T Cell Therapy
Joshua Hill | Fred Hutch; University of Washington
Fungal Infections
Chair
Kieren Marr | Johns Hopkins University School of Medicine
Candida Infections in the Immunocompromised Host
William Steinbach | Duke University Medical Center
Genetic Susceptibility for Invasive Aspergillosis
Tobias Hohl | Memorial Sloan Kettering Cancer Center
Novel Diagnostic Approaches to the Diagnosis of Invasive Aspergillosis
Sophia Koo | Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School
Pro/Con Debate: Upfront Combination Antifungal Therapy
Moderators:
- Catherine Liu | Fred Hutch; University of Washington; Seattle Cancer Care Alliance
- Joshua Schiffer | Fred Hutch; University of Washington
Debators:
- Dimitrios Kontoyiannis | The University of Texas MD Anderson Cancer Center
- Kieren Marr | Johns Hopkins University School of Medicine
Microbiome
Chair
David N. Fredricks | Fred Hutch; University of Washington
Microbiome in Transplantation
Ying Taur | Memorial Sloan Kettering Cancer Center
Gut Microbiome and GVHD
Jonathan Golob | Fred Hutch; University of Washington
Microbiome in Idiopathic Syndromes after Transplantation
Ami Bhatt | Stanford University School of Medicine
Lung Microbiome in Lung Transplantation
Ronald Collman | University of Pennsylvania School of Medicine
From Adenovirus to Zika
Chair
Steven Pergam | Fred Hutch; University of Washington; Seattle Cancer Care Alliance
Adenovirus Impact and Therapeutic Options
Janet Englund | Seattle Children's Hospital; University of Washington
HIV Infection and Transplantation
Christine Durand | Johns Hopkins School of Medicine
Zika Virus Infections in Immunocompromised Patients
Clarisse Machado | Universidade de São Paulo, Brazil
Respiratory Viruses
Chairs:
- Janet A. Englund | Seattle Children’s Hospital; University of Washington; Fred Hutch
- Per Ljungman | Karolinska University Hospital; Karolinska Institutet, Stockholm, Sweden
RSV and Parainfluenzavirus Infections in HCT Recipients
Roy Chemaly | The University of Texas MD Anderson Cancer Center
Rhinovirus in HCT Recipients
Alpana Waghmare | Seattle Children's Hospital; University of Washington; Fred Hutch
Respiratory Virus Infections in SOT Recipients
Deepali Kumar | University of Toronto
Respiratory Virus Infections in Chronic Allograft Dysfunction
Ajit Limaye | University of Washington
Panel Discussion: Challenges in Identifying Novel Clinical Endpoints for the Development of Therapeutics for Respiratory Virus infections in Immunocompromised Patients
Moderator
Per Ljungman | Karolinska University Hospital; Karolinska Institutet
Panelists:
- Roy Chemaly | The University of Texas MD Anderson Cancer Center
- Francisco Marty | Brigham and Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School
- Michael Boeckh | Fred Hutch; University of Washington
- Kieren Marr | Johns Hopkins University School of Medicine
Original Short Presentations By Trainees
Chairs:
- Julie McElrath, Fred Hutch; University of Washington
- Anna Wald, University of Washington; Fred Hutch
Therapeutic Drug Monitoring of Novel Formulations of Posaconazole in SOT Recipients
Ghady Haidar | University of Pittsburgh Medical Center
Performance of Targeted Fungal Sequencing for Culture-Independent Diagnosis of Invasive Fungal Disease
Carlos A. Gomez | Stanford University School of Medicine
Adoptive T Cell Therapy For HIV
Shabnum Patel | The George Washington University
Characterizing Monoclonal Antibodies Against Carbapenem-Resistant Klebsiella Pneumoniae
Elizabeth Diago-Navarro | Stony Brook University
Clinical Experience with Novel Cephalosporin/Beta-Lactamase Inhibitor Combinations in Solid Organ Transplant Recipients
Puja Nambiar | Cleveland Clinic
Chronic High EBV Load and T Cell Exhaustion in Pediatric Solid Organ Transplantation
Masaki Yamada | Children’s Hospital Pittsburgh
Cytomegalovirus
Chairs:
- Michael Boeckh | Fred Hutch; University of Washington
- Ajit Limaye | University of Washington; Fred Hutch
Prevention of CMV in SOT Recipients
Deepali Kumar | University of Toronto
Multivirus Infections
Joshua Schiffer | Fred Hutch; University of Washington
Antivirals to Prevent CMV in HCT
Francisco Marty | Brigham and Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School
Closing Remarks and Conclusion
Michael Boeckh | Fred Hutch; University of Washington
On June 13, 2016 Fred Hutch celebrated 25 years of achievements of the Joel Meyers Infectious Disease Endowment Scholarship with our first Symposium on Infectious Disease in the Immunocompromised Host. This special reunion honored Dr. Joel Meyers' legacy as an iconic leader in research and clinical care of infections in the immunocompromised patient. More than 140 attended the symposium to hear the latest in infectious disease research and network with colleagues.
Introduction
Larry Corey | Fred Hutch
Infection in the Immunocompromised Host: Where We Started and Where We Are Now
Phillip Pizzo | Stanford University
Introducing Antivirals at the Fred Hutch: The Early Days
James Wade | Inova Dwight and Martha Schar Cancer Institute
CMV Infection Prevention: Reflection and Forecast
John Zaia | City of Hope National Medical Center
Clostridium Difficile in Immunocompromised Patients: A Hospital Epidemiologist's View
Lucy Tompkins | Stanford University
Advances in Fungal Prophylaxis and Therapy in the Immunocompromised Host
Kieren Marr | Johns Hopkins University
Respiratory Virus Infections in the HCT Patient: Then and Now
Per Ljungman | Karolinska University Hospital, Karolinska Institute
Development of Antiviral Agents for DNA Viruses
W. Garrett Nichols | Chimerix, Inc.
The Human Microbiome
David Fredricks | Fred Hutch
Short talks by Joel Meyers scholars:
- Microbiome and HCT Outcomes
Jonathan Golob | Fred Hutch (newly selected JM scholar) - HHV-6 Infection in HCT Patients
Joshua Hill | Fred Hutch - Emerging Respiratory Virus Infections in HCT Patients
Angela Campbell | Centers for Disease Control and Prevention - IL-6 in Castleman Disease
Corey Casper | Fred Hutch
Hepatitis C: A Model for Modern Viral Chemotherapy
M. Michelle Berrey | Chimerix, Inc.
Immunotherapy of Infectious Diseases
Stanley Riddell | Fred Hutch
ID in Immunocompromised Host: Future Challenges
Michael Boeckh | Fred Hutch